Director, Early Stage CMC Program Lead

About Generate Biomedicines

generatebiomedicines.com

Generate:Biomedicines is a therapeutics company that combines machine learning, computational biology, and biological engineering to design and develop precision protein medicines and antibodies. Using generative AI and lab-driven engineering, the company builds targeted biologics and epitope-focused candidates, advancing a pipeline from discovery through clinical development. Its clinical-stage programs include GB-0895, a long‑acting anti‑TSLP antibody progressing to global Phase 3 studies, and the company has recently completed an initial public offering. Generate was incubated by Flagship Pioneering and emphasizes platform-driven discovery to accelerate novel biologic therapeutics.

Recent company news

Seton Hall University

AI Meets Biotech The High Stakes IPO of Generate Biomedicines – The Stillman Exchange

4 days ago

PR Newswire

Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering

2 weeks ago

The Wall Street Journal

Generate Biomedicines Shares Plummet After $400 Million Market Debut

2 weeks ago

BioPharma Dive

Generate caps a strong month for biotech IPOs with $400M offering

2 weeks ago

Yahoo Finance

Generate Biomedicines (GENB) Valuation Check After Recent Share Price Weakness

5 days ago